The findings suggest a delay in the progression to end-stage renal disease (ESRD) and a slower decline in kidney function, as evidenced by a significant difference in the time to initiation of dialysis between GLP-1 agonist-treated patients and those receiving other antidiabetic agents66,67. This evidence concerns the gene GCG and stage 5 chronic kidney disease.